FREEFLOW — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Sift Biosciencessiftbio.cominNov 2025
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells.
AI & Machine LearningBiotechHealthtechSan Carlos, US
Yue Clare Lou(Co-Founder & CEO)inYue Lou(Executive Officer, Director)
BoardKevin Barrett(Director)Altar Munis(Director)
Co-investorsEisai Innovation, Inc.SBI HoldingsFifty Years
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.